Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

被引：464

作者：

Johnson, J. A. ^{[1
,2
]}

Gong, L. ^{[3
]}

Whirl-Carrillo, M. ^{[3
]}

Gage, B. F. ^{[4
]}

Scott, S. A. ^{[5
]}

Stein, C. M. ^{[6
]}

Anderson, J. L. ^{[7
]}

Kimmel, S. E. ^{[8
,9
,10
]}

Lee, M. T. M. ^{[11
]}

Pirmohamed, M. ^{[12
]}

Wadelius, M. ^{[13
]}

Klein, T. E. ^{[3
]}

Altman, R. B. ^{[3
,14
]}

机构：

[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA

[2] Univ Florida, Ctr Pharmacogenom, Gainesville, FL USA

[3] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[4] Washington Univ, Dept Internal Med, St Louis, MO USA

[5] Mt Sinai Hosp, Dept Genet & Genom Sci, New York, NY USA

[6] Vanderbilt Univ, Nashville, TN USA

[7] Intermt Healthcare, Salt Lake City, UT USA

[8] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA

[9] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA

[10] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA

[11] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan

[12] Univ Liverpool, Liverpool L69 3BX, Merseyside, England

[13] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

[14] Stanford Univ, Dept Bioengn, Palo Alto, CA 94304 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 90卷 / 04期

基金：

瑞典研究理事会; 美国国家卫生研究院;

关键词：

RISK; ANTICOAGULATION; POLYMORPHISMS; ASSOCIATION; RESISTANCE; PREDICT;

D O I：

10.1038/clpt.2011.185

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for similar to 50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb.org based on new developments in the field.(1)

引用

页码：625 / 629

页数：5

共 29 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2] Pharmacology and management of the vitamin K antagonists [J].

Ansell, Jack ;

Hirsh, Jack ;

Hylek, Elaine ;

Jacobson, Alan ;

Crowther, Mark ;

Palareti, Gualtiero .

CHEST, 2008, 133 (06) :160S-198S

[3] CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study [J].

Caraco, Y. ;

Blotnick, S. ;

Muszkat, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) :460-470

[4] Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation [J].

Eckman, Mark H. ;

Rosand, Jonathan ;

Greenberg, Steven M. ;

Gage, Brian F. .

ANNALS OF INTERNAL MEDICINE, 2009, 150 (02) :73-U31

[5] Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study) [J].

Epstein, Robert S. ;

Moyer, Thomas P. ;

Aubert, Ronald E. ;

O'Kane, Dennis J. ;

Xia, Fang ;

Verbrugge, Robert R. ;

Gage, Brian F. ;

Teagarden, J. Russell .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (25) :2804-2812

[6] Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy [J].

Ferder, N. S. ;

Eby, C. S. ;

Deych, E. ;

Harris, J. K. ;

Ridker, P. M. ;

Milligan, P. E. ;

Goldhaber, S. Z. ;

King, C. R. ;

Giri, T. ;

McLeod, H. L. ;

Glynn, R. J. ;

Gage, B. F. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) :95-100

[7] Genetic Warfarin Dosing Tables Versus Algorithms [J].

Finkelman, Brian S. ;

Gage, Brian F. ;

Johnson, Julie A. ;

Brensinger, Colleen M. ;

Kimmel, Stephen E. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (05) :612-618

[8] Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [J].

Gage, B. F. ;

Eby, C. ;

Johnson, J. A. ;

Deych, E. ;

Rieder, M. J. ;

Ridker, P. M. ;

Milligan, P. E. ;

Grice, G. ;

Lenzini, P. ;

Rettie, A. E. ;

Aquilante, C. L. ;

Grosso, L. ;

Marsh, S. ;

Langaee, T. ;

Farnett, L. E. ;

Voora, D. ;

Veenstra, D. L. ;

Glynn, R. J. ;

Barrett, A. ;

McLeod, H. L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) :326-331

[9] Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues [J].

Gage, Brian F. ;

Lesko, Lawrence J. .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 25 (01) :45-51

[10] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].

Higashi, MK ;

Veenstra, DL ;

Kondo, LML ;

Wittkowsky, AK ;

Srinouanprachanh, SL ;

Farin, FM ;

Rettie, AE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698

← 1 2 3 →